Search Within

Viswatej Avutu

Formats
  1. Meeting Abstract (19)
  2. Journal Article (13)
  3. Guidelines (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Hematology-Oncology Fellows (35)
  2. Department of Medicine (30)
  3. Solid Tumor Oncology Division (30)
  4. Sarcoma Service (29)
  5. Hematologic Malignancies, Division of (21)
  6. Weinberg Fellows (20)

More Groups

People
  1. William Tap (23)
  2. Mark Dickson (20)
  3. Ciara Kelly (19)
  4. Mary Keohan (19)
  5. Mrinal Gounder (19)
  6. Sandra D'Angelo (19)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (8)
  4. 2022 (11)
  5. 2021 (1)
  6. 2020 (4)
Publications
  1. Journal of Clinical Oncology (16)
  2. Journal of Adolescent and Young Adult Oncology (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. Journal for ImmunoTherapy of Cancer (2)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (17)
  2. American Association for Cancer Research (3)
  3. Mary Ann Liebert, Inc (3)
  4. Biomed Central Ltd (2)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (35)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group
    Review

    Crane, J. N.; Douglass, D. P.; Oberoi, S.; Collins, N. B.; Gupta, A.; Metts, J. L.; Avutu, V.; Dela Cruz, F. S.; Davis, J. L.; Federman, N. C.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save
  • A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Movva, S.; Kelly, C. M.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Nacev, B. A.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Harmonization of the upfront osteosarcoma treatment paradigm for adolescents and young adults
    Journal Article

    Daukshus, N. P.; Avutu, V.; Long Sarro, E.; Kinnaman, M. D.; Slotkin, E. K.; Thornton, K.; Dickson, M. A.; Sklarin, N. T.; Tap, W. D.; Glade Bender, J.
    Journal of Adolescent and Young Adult Oncology (2025)

    Fulltext@MSK | Save
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
    Journal Article

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Avutu, V.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma
    Meeting Abstract

    Avutu, V.; Livingston, J. A.; Federman, N.; Cranmer, L. D.; Gaspar, N.; Toulmonde, M.; Pressey, J. G.; Brahmi, M.; Poklepovic, A. S.; Shi, Q.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bradic, M.; Desir, R.; Kelly, C. M.; Movva, S.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save